Rouprêt Morgan, Hupertan Vincent, Yates David R, Catto James W F, Rehman Ishtiaq, Meuth Mark, Ricci Sylvie, Lacave Roger, Cancel-Tassin Géraldine, de la Taille Alexandre, Rozet François, Cathelineau Xavier, Vallancien Guy, Hamdy Freddie C, Cussenot Olivier
Institute for Cancer Studies and Academic Urology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK.
Clin Cancer Res. 2007 Mar 15;13(6):1720-5. doi: 10.1158/1078-0432.CCR-06-2467.
The diagnosis of localized prostate cancer is difficult due to a lack of cancer-specific biomarkers. Many patients require repeat prostate biopsies to diagnose the disease. We investigated whether aberrant promoter hypermethylation in prostatic fluid could reliably detect prostate cancer.
Urine samples were collected after prostate massage from 95 patients with localized prostate cancer undergoing radical prostatectomy (63 pT(1), 31 pT(2), and 1 pT(3)) and from 38 control patients. Ten genes (GSTP1, RASSF1a, ECDH1, APC, DAPK, MGMT, p14, p16, RARbeta2, and TIMP3) were investigated using quantitative real-time methylation-specific PCR. Receiver operator curves were generated.
The frequency of gene methylation ranged from 6.3% (p14) to 83.2% (GSTP1) in prostate cancer patients. At least one gene was hypermethylated in 93% of cancer patients. The specificity of methylation was 0.74. Methylation was significantly more frequent (P < 0.05) in cancer than control patients for all genes except p14 and p16. According to receiver operator curve analysis, the four-gene combination of GSTP1 (0.86), RASSF1a (0.85), RARbeta2 (0.80), and APC (0.74) best discriminated malignant from nonmalignant cases. The sensitivity and accuracy of this four-gene set were 86% and 89%, respectively.
The presence of aberrant methylation in urinary cells obtained after prostate massage is significantly associated with prostate cancer. A panel of four genes could stratify patients into low and high risk of having prostate cancer and optimize the need for repeat prostatic biopsies.
由于缺乏癌症特异性生物标志物,局限性前列腺癌的诊断较为困难。许多患者需要重复进行前列腺活检以诊断该病。我们研究了前列腺液中异常的启动子高甲基化是否能够可靠地检测出前列腺癌。
从95例接受根治性前列腺切除术的局限性前列腺癌患者(63例pT(1)期、31例pT(2)期和1例pT(3)期)以及38例对照患者在前列腺按摩后收集尿液样本。使用定量实时甲基化特异性PCR研究10个基因(GSTP1、RASSF1a、ECDH1、APC、DAPK、MGMT、p14、p16、RARbeta2和TIMP3)。生成受试者操作曲线。
前列腺癌患者中基因甲基化频率在6.3%(p14)至83.2%(GSTP1)之间。93%的癌症患者中至少有一个基因发生高甲基化。甲基化的特异性为0.74。除p14和p16外,所有基因在癌症患者中的甲基化频率均显著高于对照患者(P < 0.05)。根据受试者操作曲线分析,GSTP1(0.86)、RASSF1a(0.85)、RARbeta2(0.80)和APC(0.74)这四个基因的组合对恶性和非恶性病例的区分效果最佳。该四基因组合的敏感性和准确性分别为86%和89%。
前列腺按摩后获得的尿细胞中异常甲基化的存在与前列腺癌显著相关。一组四个基因可将患者分为前列腺癌低风险和高风险组,并优化重复前列腺活检的必要性。